| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_116c851e729089df9a427027272fa290 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4409
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4418
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4425
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-08 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4418 |
| filingDate |
2012-03-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d8394a03bd6b67a9f909c5fd19838a7d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bbd254f690fb45f44dbc15c0cd26365f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f73d4cb8301f81b46cccc8565736bf05
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0ad3f30281f91f0b9a0df681aa6d39df
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5ee1f5315cd0ac18cb9166df26edcf72 |
| publicationDate |
2014-02-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-2691075-A1 |
| titleOfInvention |
Otamixaban formulations with improved stability |
| abstract |
The invention relates to a pharmaceutical composition comprising methyl (2R.3R)-2-{3-[amino(imino)methyl]benzyl}-3-{[4-(1-oxidopyridin-4-yl)benzoyl]amino}butanoate or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable acidic reacting compound or to an aqueous solution or dispersion of the composition as well as a process for the preparation of the same, methods of using such compositions to treat subjects suffering from conditions which can be ameliorated by the administration of an inhibitor of Factor Xa. |
| priorityDate |
2011-03-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |